ALXO News and Press, ALX Oncology Holdings Inc. From 11/23/21

The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology Holdings (ALXO) Investor Presentation

ALX Oncology (NASDAQ:ALXO): Q3 GAAP EPS of -$0.61 misses by $0.14. Press Release. For further details see: ALX Oncology EPS misses by $0.14

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quart...

Gainers: Dover Motorsports (NYSE:DVD) +57%. TDH Holdings (NASDAQ:PETZ) +40%. New Relic (NYSE:NEWR) +35%. Roblox (NYSE:RBLX) +32%. Guaranty Federal Bancshares (NASDAQ:GFED) +31%. Bit Brother (NASDAQ:BTB) +29%. Altimeter Growth (NASDAQ:AGC) +26%. Altimeter Growth (NASDAQ:AGCUU) +26%. Katapult (...

Shares of ALX Oncology (NASDAQ:ALXO) are down 5% premarket after the company released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. Updated results were in two cohorts: gastric/gastroesophageal junction cancer patients receiving evorpacept plus Her...

-- ORR of 72.2%, mDOR of 14.8 months, 12-month OS rate of 79%, and mOS of 17.1 months in Patients with > 2L HER2 Positive Gastric/Gastroesophageal Junction Cancer -- -- 12-month OS rate of 87.5% and mOS not reached in Patients with 1L Head and Neck Cancer -- ...

ALX Oncology (ALXO -23.3%) shares have lost more than a fifth to reach a 12-month low after the company released preliminary data for its lead asset evorpacept from a Phase 1/2 trial in combination with chemotherapy azacitidine in myelodysplastic syndromes (“MDS”). As of mi...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the Company will be presenting early ...

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in...

Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugates Expands ALX Oncology’s pipeline of drug candidates based on expertise in protein engineeri...